Riccardo Mazza։ Personalized Anticoagulation in Atrial Fibrillation
Riccardo Mazza, Cardiology Resident at University Vita-Salute San Raffaele, shared a post on LinkedIn about a recent article he co-authored with Cosmo Godino, adding:
՛՛Our response to the Letter to the Editor by Magdelijns et al. has been published in the Journal of Thrombosis and Haemostasis.
The concept of ‘one-size-fits-all’ anticoagulation may have limitations in contemporary AF management.
Personalized anticoagulation is progressively moving from theoretical consideration to clinical discussion.
We are grateful for the ongoing scientific discussion and look forward to the results of the DOAC-FRAIL trial.՛՛
Title: Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events: reply
Authors: Cosmo Godino, Riccardo Mazza
Read the Full Article on Journal of Thrombosis and Haemostasis․
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids